Assessing dydrogesterone efficacy in endometrial protection for abnormal uterine bleeding from endometrial hyperplasia

Yuxiang Zhou, Xiulan Li, Yanmei Li, Qing Liu

Abstract

This study was designed to determine the effectiveness of dydrogesterone in protecting the endometrium in females experiencing irregular uterine bleeding arising from endometrial hyperplasia. A cohort of 112 patients suffering from abnormal uterine bleeding due to endometrial hyperplasia, who underwent hysteroscopic surgery at our institution between January 2019 and May 2023, were assigned to two groups. Following the surgery, dydrogesterone was provided to the observation group. In contrast, medroxyprogesterone acetate-ethinyl estradiol tablets were utilized for the control group in conventional treatment. Primary outcomes included symptom improvement, treatment effectiveness, and safety profiles. Secondary outcomes involved assessing health-related life quality by employing the SF-36 questionnaire. The base characteristics were nearly the same between groups (P > 0.05). Following treatment, the observation group exhibited significantly greater improvements in symptoms and treatment effectiveness as opposed to the control group (P < 0.05), without an increase in adverse reactions. Moreover, while both groups experienced significant enhancements in SF-36 scores from baseline, the observation group showed more pronounced improvements in certain dimensions (P < 0.05). Dydrogesterone treatment following hysteroscopic surgery for females with abnormal uterine bleeding and endometrial hyperplasia demonstrates superior efficacy in endometrial protection and symptom management, without escalating adverse effects. The observed enhancements in quality of life underscore its clinical utility, suggesting dydrogesterone as a valuable therapeutic option in this clinical context.

Full Text:

PDF

References

Marnach ML, Laughlin-Tommaso SK, Stewart EA, Weaver

AL, Williams AR, Hesley GK and Seppala MT.

Evaluation and Management of Abnormal Uterine

Bleeding. Mayo Clin Proc. 2019;94(2):326-335.

Khafaga A, Goldstein SR, Klein TA, Hearn ST, Graham CL,

Navarro SA and Fielding RA. Abnormal Uterine

Bleeding. Obstet Gynecol Clin North Am.

;46(4):595-605.

Whitaker L, Critchley HO, Smith CW, Lloyd JW, Stanton

AM, Parker CJ and Dawson AE. Abnormal uterine

bleeding. Best Pract Res Clin Obstet Gynaecol.

; 34: 54-65.

Li Weiping, Zhang Z, Liu Y, Huang S, Fang J, Wang L and

Chen X. The concept of minimally invasive surgery

in gynecology and the future of transvaginal surgery

[J].

Chinese

Journal

Medicine,2023,33(03):1-5.

of

Modern

Ma Xiao-xin, Yu Qi, Xiangyang X, Liu JL, Wang RJ, Huang

Y and Zhang J. Chinese expert consensus on long

term Management of endometrial hyperplasia in

menopausal transition and postmenopausal period

(2022 edition) [J]. Chinese Journal of Applied

Gynecology and Obstetrics,202,38(12):1195-1200.

Ring KL, Mills AM, Modesitt SC, Carlson M, Brenner L,

Perkowski J and Stewart KG. Endometrial

Hyperplasia. Obstet Gynecol. 2022;140(6):1061

Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R and

Patel S. Therapeutic options for management of

endometrial

hyperplasia.

;27(1):e8.

J Gynecol Oncol.

Jewson M, Purohit P, Lumsden MA, Hecht T, McMahon D,

Riggall K and Whitehead H. Progesterone and

abnormal uterine bleeding/menstrual disorders. Best

Pract Res Clin Obstet Gynaecol. 2020; 69: 62-73.

Li Lu, Wang Hongmei, Shen Yi and Zhang

Xiao.Development and performance test of SF-36

health survey scale in Chinese [J]. Chinese Journal

of Preventive Medicine,2002(02):38-42. (in Chinese)

Braun MM, Overbeek-Wager EA, Grumbo RJ, Meeks J,

Langston P and Turner DG. Diagnosis and

Management of Endometrial Cancer. Am Fam

Physician. 2016;93(6):468-474.

Zhang YF, Fan Y, Mu Y, Li JK, Wang XF and Chen LM.

Efficacy of Oral Medications or Intrauterine Device

Delivered Progestin in Patients with Endometrial

Hyperplasia with or without Atypia: A Network

Meta-Analysis. J Clin Med. 2023;12(8):2980.

Su Meixia, Huang Xiaoqu, Pan Jieting, Chen Xueli, Zhang

Li and Wang Yun. Effects of dydrogesterone and

mifepristone therapy on menstrual volume,

endometrial thickness, hemoglobin concentration

and sex hormone levels in patients with

dysfunctional

uterine

bleeding

during

perimenopause [J]. Journal of Guangzhou Medical

University, 2019,48(04):12-15.

Gu Xiangying, Zhang Yixin, Liu Mei, Chen Xiao, Wang

Qin and Zhou Jie. Clinical application of compound

oral

contraceptives for non-contraception [J].

Journal of Practical Obstetrics and Gynecology,

, 35(10):726-729.

Xie Qning, Li Feng, Yang Min, Zhang Huijun, Chen Xia

and Wang Yanyan. Effect analysis of different

progesterone (dydrogesterone and progesterone

capsules) in the treatment of abnormal uterine

bleeding in perimenopause and comparison of side

effects [J]. Electronic Journal of Applied

Gynecology Endocrinology,20,7(35):20-23.

Yang Huomei, Song Xiaoxia, Zhang Long, Wang Li, Zhao

Meiling and Chen Yufeng.Evaluation of clinical

efficacy of dydrogesterone in the treatment of simple

hyperplasia of endometrial [J]. Contemporary

Medicine, 201,27(29):30-33.

Liu Hengfang, Zhou Ming, Zhang Wei, Li Rui, Zhao Yanan

and Fang Yuan.Clinical effect of dydrogesterone

assisted hysteroscopic resection of endometrial

polyps in patients with endometrial polyps [J].

Journal of Systems Medicine, 2002,7(15):151-155.

Refbacks

  • There are currently no refbacks.